GlassScriptPhysician profile
Jean M Welsh
NPI 1861592461
$24,493.69
in general payments reported to CMS, 2019-2025
65 companies · $2,359 in 2025
The $2,359 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $6,974 · 2020: $2,478 · 2021: $4,430 · 2022: $2,858 · 2023: $3,101 · 2024: $2,294 · 2025: $2,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,991 · Travel and Lodging: $743 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,991.22 |
| Travel and Lodging | $743.04 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $2,964.52 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $1,861.10 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,844.56 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $1,469.51 | 2019-2023 | Leqvio |
| Novo Nordisk As | $1,467.76 | 2019-2022 | |
| Novo Nordisk INC | $1,343.14 | 2019-2025 | Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $1,290.83 | 2021 | |
| Sunovion Pharmaceuticals INC. | $1,271.79 | 2019-2022 | |
| Lilly USA, LLC | $1,044.83 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Allergan, INC. | $797.39 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $622.68 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $594.01 | 2019-2025 | Fanapt, Hetlioz |
| Astellas Pharma US INC | $571.55 | 2019-2024 | Veozah |
| Indivior INC. | $504.61 | 2019-2025 | Sublocade |
| Amarin Pharma, INC. | $491.56 | 2019-2022 |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $484.08 | 2023-2025 | Aptiom, Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.65 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $409.60 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Ardelyx, INC. | $399.90 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $397.75 | 2020-2025 | |
| Ucb, INC. | $384.69 | 2019-2025 | Briviact, Nayzilam |
| Pfizer INC. | $319.04 | 2020-2025 | |
| Amgen INC. | $254.85 | 2022-2025 | Evenity, Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $249.96 | 2020-2025 | Caplyta |
| Cumberland Pharmaceuticals, INC. | $221.92 | 2019-2025 | Kristalose |
| Exact Sciences Corporation | $213.44 | 2023-2025 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $197.99 | 2021-2022 | |
| Corcept Therapeutics | $195.72 | 2019-2021 | |
| Eisai INC. | $164.99 | 2021-2022 | |
| Abbott Laboratories | $130.50 | 2021-2024 | Freestyle Libre 3 |
| Redhill Biopharma INC. | $124.46 | 2021-2022 | |
| Alkermes, INC. | $123.15 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.44 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $109.08 | 2024-2025 | Ajovy, Austedo Xr |
| Ironwood Pharmaceuticals, INC | $100.49 | 2019-2020 | |
| Inspire Medical Systems, INC. | $98.53 | 2024-2025 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $97.70 | 2022 | |
| Evoke Pharma, INC. | $91.09 | 2020-2024 | |
| Daiichi Sankyo INC. | $90.46 | 2021 | |
| Ascensia Diabetes Care US INC. | $83.40 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.69 | 2020-2024 | Xifaxan |
| Neurelis, INC. | $65.10 | 2023-2025 | Valtoco |
| Phadia US INC. | $65.09 | 2019-2024 | Immunocap |
| Lundbeck LLC | $61.17 | 2023-2025 | Rexulti, Vyepti |
| Janssen Biotech, INC. | $57.27 | 2019-2023 | Symtuza |
| Scilex Pharmaceuticals INC. | $51.11 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $48.65 | 2022 | |
| Corium, LLC | $47.80 | 2022-2023 | Azstarys |
| Janssen Pharmaceuticals, INC | $46.59 | 2023 | Xarelto |
| Esperion Therapeutics, INC. | $46.03 | 2021-2025 | Nexletol |
| Jazz Pharmaceuticals INC. | $35.51 | 2021-2022 | |
| Orexo US, INC. | $34.37 | 2019-2024 | Zubsolv |
| Actelion Pharmaceuticals US, INC. | $30.50 | 2023 | Opsumit |
| Nestle Healthcare Nutrition INC. | $27.01 | 2021 | |
| Optinose US, INC. | $23.15 | 2024 | |
| Bausch Health US, LLC | $23.14 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.42 | 2023 | Rexulti |
| Neurocrine Biosciences, INC. | $19.67 | 2024 | Ingrezza |
| Currax Pharmaceuticals LLC | $16.53 | 2024 | Onzetra Xsail, Contrave |
| Grifols USA, LLC | $15.31 | 2019 | |
| Glaxosmithkline, LLC. | $13.92 | 2023 | Arexvy, Shingrix |
| Biocryst US Sales Co., LLC | $13.76 | 2025 | Orladeyo |
| Hikma Pharmaceuticals USA | $11.09 | 2021 | |
| Eyevance Pharmaceuticals LLC | $11.09 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,568.86 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Welsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.